```html

Wasting Disease (Cachexia) – A Patient‑Friendly Medical Guide

Overview

Cachexia (pronounced “ka‑kee‑ksee‑uh”) is a complex metabolic syndrome characterized by severe loss of body weight, muscle mass, and fat tissue. It is most commonly seen in people with chronic illnesses such as advanced cancer, heart failure, chronic obstructive pulmonary disease (COPD), chronic kidney disease, and AIDS.

• Who it affects: Up to 80 % of patients with late‑stage cancer develop cachexia; prevalence in heart‑failure patients is 5‑15 %; in COPD it ranges 20‑30 %.<sup>1,2</sup>
• Why it matters: The weight loss is not simply due to reduced food intake; inflammatory cytokines, hormonal changes, and altered metabolism cause a catabolic state that cannot be reversed by ordinary nutritional support alone.
• Impact: Cachexia reduces functional capacity, worsens quality of life, and is an independent predictor of mortality—median survival after diagnosis is often less than a year in cancer‑related cachexia.<sup>3</sup>

Symptoms

Symptoms arise from the progressive loss of lean body mass and from the underlying disease. They can be subtle at first and evolve quickly.

General

• Unintentional weight loss: ≥5 % of body weight within 6–12 months, or >2 % in a person with a BMI <20 kg/m².
• Fatigue / loss of energy: Feelings of exhaustion that are disproportionate to activity level.
• Decreased appetite (anorexia): Often the first patient‑reported complaint.

Musculoskeletal

• Muscle weakness and reduced grip strength.
• Visible thinning of the arms, thighs, and calves.
• Difficulty climbing stairs, getting out of a chair, or lifting objects.

Metabolic / Laboratory

• Elevated inflammatory markers: C‑reactive protein (CRP), interleukin‑6 (IL‑6), tumor necrosis factor‑α (TNF‑α).
• Low serum albumin and pre‑albumin.
• Evidence of insulin resistance or hyperglycemia in some patients.

Gastrointestinal

• Nausea, early satiety, or dysgeusia (altered taste).
• Dry mouth or xerostomia that worsens eating difficulties.

Psychological

• Depression or anxiety secondary to body‑image changes and loss of independence.
• Reduced motivation to engage in self‑care.

Causes and Risk Factors

Cachexia is not a disease on its own; it is a syndrome triggered by a combination of metabolic, inflammatory, and neurohormonal factors.

Underlying Diseases

• Cancer: Particularly pancreatic, lung, gastric, and colorectal cancers; tumors release cytokines (e.g., IL‑1, IL‑6, TNF‑α) that drive catabolism.
• Heart failure: Chronic sympathetic activation and cytokine release accelerate muscle proteolysis.
• Chronic obstructive pulmonary disease (COPD): Persistent hypoxia and systemic inflammation.
• Chronic kidney disease (CKD) – stage 5: Uremic toxins and metabolic acidosis.
• HIV/AIDS: Opportunistic infections and viral proteins.

Pathophysiological Drivers

• Pro‑inflammatory cytokines: TNF‑α, IL‑1β, IL‑6, interferon‑γ.
• Hormonal dysregulation: Decreased anabolic hormones (testosterone, IGF‑1) and increased catabolic hormones (cortisol, catecholamines).
• Protein‑turnover imbalance: Up‑regulation of the ubiquitin‑proteasome pathway leading to muscle breakdown.
• Metabolic inefficiency: Elevated resting energy expenditure (REE) of 10‑30 % above normal.

Risk Factors

• Advanced stage of underlying disease.
• Male sex (higher muscle mass provides a larger substrate for loss).
• Low baseline BMI (<22 kg/m²).
• Presence of systemic inflammation (CRP > 5 mg/L).
• Smoking and chronic alcohol use (exacerbate inflammation).

Diagnosis

Diagnosing cachexia requires a combination of clinical assessment, objective measurements, and laboratory testing.

Clinical Criteria (International Consensus, 2011)

A patient is considered cachectic when any of the following are present:

1. Weight loss >5 % over 12 months (or <5 % with BMI < 20 kg/m²).
2. Weight loss >2 % in an individual with a BMI <20 kg/m².
3. Weight loss >2 % with sarcopenia (low muscle mass measured by imaging).

Objective Assessments

• Body composition analysis: Dual‑energy X‑ray absorptiometry (DEXA), bioelectrical impedance analysis (BIA), or CT/MRI cross‑sectional area of the psoas muscle.
• Hand‑grip strength: Dynamometer reading < 30 kg (men) or < 20 kg (women) indicates reduced muscle function.
• Resting energy expenditure: Indirect calorimetry can confirm hypermetabolism.

Laboratory Tests

• Complete blood count (CBC) – to rule out anemia, infection.
• Serum albumin, pre‑albumin, transferrin – markers of nutritional status.
• CRP, ESR – inflammation.
• Lactate dehydrogenase (LDH), liver function tests – often altered in cancer.
• Hormonal profile (testosterone, IGF‑1) if endocrine contribution is suspected.

Imaging

CT scans performed for cancer staging are routinely used to measure muscle area at the L3 vertebral level—an accepted surrogate for whole‑body lean mass.

Treatment Options

Treatment is multidisciplinary: targeting the underlying disease, correcting metabolic abnormalities, and providing nutritional and physical support.

1. Disease‑Directed Therapy

• Cancer: Chemotherapy, targeted therapy, immunotherapy, or palliative radiation can reduce tumor burden and cytokine production.
• Heart failure: Optimized guideline‑directed medical therapy (ACE‑I/ARB, beta‑blockers, SGLT2 inhibitors).
• COPD: Long‑acting bronchodilators, pulmonary rehabilitation, and oxygen therapy.

2. Pharmacologic Agents for Cachexia

Drug	Mechanism	Typical Use
Megestrol acetate	Progestin – stimulates appetite & reduces catabolism	Advanced cancer cachexia; 400–800 mg/day
Olanzapine	Dopamine/serotonin antagonist – improves taste, appetite	When nausea or altered taste are prominent
Enobosarm (Selective Androgen Receptor Modulator)	Promotes muscle protein synthesis	Under clinical trial; promising for muscle preservation
Metformin	Improves insulin sensitivity, may lower REE	Adjunct in insulin‑resistant cachexia
NSAIDs (e.g., celecoxib)	Reduces inflammatory cytokine production	In patients with high CRP, careful GI monitoring required

3. Nutritional Interventions

• Calorie‑dense oral supplements: 1.5–2 × estimated energy needs (≈30–35 kcal/kg/day).
• High‑protein formulas: 1.5–2.0 g protein/kg/day, enriched with branched‑chain amino acids (leucine).
• Enteral feeding: Nasogastric or percutaneous endoscopic gastrostomy (PEG) when oral intake < 500 kcal/day for > 2 weeks.
• Parenteral nutrition: Reserved for severe malabsorption or when enteral route is contraindicated.

4. Exercise & Physical Therapy

• Resistance training: 2–3 sessions/week, 30–45 minutes, focusing on major muscle groups.
• Aerobic activity: Low‑intensity walking or cycling 150 minutes/week to maintain cardiovascular fitness.
• Combining exercise with protein supplementation yields the greatest gains in lean mass.<sup>4</sup>

5. Symptom‑Focused Care

• Anti‑nausea agents (ondansetron, metoclopramide) to improve oral intake.
• Management of depression/anxiety (counseling, SSRIs) to boost motivation.
• Dental care & oral hygiene to reduce pain while eating.

Living with Wasting Disease (Cachexia)

Adapting daily habits can help maintain strength and quality of life.

Nutrition Tips

• Eat small, frequent meals (5–6 per day) rather than three large ones.
• Choose calorie‑dense foods: nut butters, avocado, cheese, smoothies with full‑fat milk or yogurt.
• Add healthy oils (olive, MCT oil) to soups, mashed potatoes, or sauces.
• Use spices, herbs, or flavor enhancers to combat dysgeusia.
• Keep a food diary and involve a registered dietitian for personalized plans.

Physical Activity

• Start with gentle resistance bands; progress as tolerated.
• Incorporate seated or standing leg lifts while watching TV.
• Consider a supervised exercise program at a cancer rehab or cardiac rehab center.

Emotional & Social Support

• Join support groups (online or in‑person) for cachexia or the underlying disease.
• Engage family members in meal preparation to make eating a shared activity.
• Seek mental‑health counseling if depression, anxiety, or loss of purpose becomes overwhelming.

Practical Daily Strategies

• Maintain a regular sleep schedule; poor sleep worsens catabolism.
• Stay hydrated—aim for 1.5–2 L of fluid daily unless fluid restriction is ordered.
• Monitor weight at least three times per week; a sudden drop > 2 % warrants medical review.
• Carry a “nutrition emergency kit” (protein bars, oral supplement packets) for days when appetite is low.

Prevention

Because cachexia develops secondary to chronic disease, primary prevention focuses on early detection and optimal management of the underlying condition.

• Screen high‑risk patients annually: Weight, BMI, and grip strength for cancer, heart‑failure, COPD, and CKD cohorts.
• Control inflammation: Use disease‑modifying therapies (e.g., anti‑TNF agents in rheumatoid arthritis) that may lower systemic cytokine load.
• Early nutritional counseling: Initiate dietitian support at diagnosis of a high‑risk disease.
• Physical activity preservation: Encourage regular exercise from the time of diagnosis, adapting intensity as disease progresses.
• Avoid smoking and excess alcohol: Both amplify inflammatory pathways.

Complications

If left untreated, cachexia can lead to serious, life‑threatening complications:

• Severe malnutrition: Albumin < 2.5 g/dL, impaired wound healing, increased infection risk.
• Respiratory muscle weakness: Higher incidence of pneumonia and respiratory failure.
• Cardiomyopathy: Loss of cardiac muscle mass --> heart failure exacerbation.
• Reduced tolerance to chemotherapy or other disease‑specific treatments, leading to dose reductions or treatment discontinuation.
• Psychosocial decline: Isolation, depression, and loss of independence.
• Higher mortality: Cachexia is an independent predictor of 6‑month mortality in advanced cancer (hazard ratio 2.5–3.0).<sup>5</sup>

When to Seek Emergency Care

---

Sources: 1. Fearon K et al. Lancet Oncol. 2011; 2. Anker SD et al. JACC. 2014; 3. von Haehling S et al. Nat Rev Dis Primers. 2020; 4. Phoenix C et al. J Clin Oncol. 2015; 5. Laviano A et al. Clinical Nutrition. 2022. Additional information from Mayo Clinic, CDC, NIH, WHO, and Cleveland Clinic.

```